Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biovaxys Technology Corp. (BIOV.CN)

Biovaxys Technology Corp. (BIOV.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 13,556
  • Shares Outstanding, K 26,070
  • Annual Sales, $ 0 K
  • Annual Income, $ -230 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 202.42
Trade BIOV.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings -0.01 on 07/31/20
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.340 +47.06%
on 02/04/21
0.780 -35.90%
on 02/16/21
+0.125 (+33.33%)
since 02/03/21
3-Month
0.140 +257.14%
on 01/08/21
0.780 -35.90%
on 02/16/21
+0.230 (+85.19%)
since 12/03/20

Most Recent Stories

More News
Stocks in play: BioVaxys Technology Corp.

Announced today that it is assessing steps to modify BVX-0320 and Covid-T, its SARS-CoV-2 vaccine candidate ...

BIOV.CN : 0.500 (-3.85%)
As Additional COVID Variants Surface, Questions Arise to Effectiveness of Vaccines to Combat New Strains

, /PRNewswire/ -- The epic global race to solve the COVID-19 crisis has just gotten a be a more of a puzzle with the emergence of new variants. The existing vaccines have been based on research centered...

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
JNJ : 156.22 (-1.76%)
PFE : 34.39 (+2.63%)
MRNA : 131.22 (-10.62%)
INO : 9.56 (-4.59%)
BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
BioVaxys Announces Appointment To Its Scientific Advisory Board

, /PRNewswire/ --BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic...

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients

, /PRNewswire/ -- Ovarian cancer and its rising incidence rate is a growing concern worldwide and the rising incidence of ovarian cancer will be driving the ovarian cancer drugs market for years to come....

BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)
ONTX : 1.1500 (-4.17%)
ZIOP : 4.68 (-7.69%)
EVFM : 3.60 (-8.86%)
NKTR : 23.44 (-1.26%)
BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF"BioVaxys" or "Company") announced today that it has signed a Term Sheet ("Term Sheet") with BioElpida S.A.S. ("BioElpida")...

LMNGF : 0.3951 (-2.49%)
BIOV.CN : 0.500 (-3.85%)
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us

, /PRNewswire/ --   -  Rollouts of two approved COVID-19 vaccines have for the past few months started making their way into markets around the world. Amid the attention given to COVID vaccines, vaccines...

BIOV.CN : 0.500 (-3.85%)
BNTX : 97.25 (-7.36%)
MRNA : 131.22 (-10.62%)
REGN : 446.73 (-1.79%)
MRK : 73.30 (+0.62%)
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us

Rollouts of two approved COVID-19 vaccines have for the past few months started making their way into ...

BNTX : 97.25 (-7.36%)
REGN : 446.73 (-1.79%)
MRNA : 131.22 (-10.62%)
MRK : 73.30 (+0.62%)
BIOV.CN : 0.500 (-3.85%)
Stocks in play: BioVaxys Technology Corp.

Announced today that they have entered into a broad collaboration for the co-development, joint commercialization, ...

BIOV.CN : 0.500 (-3.85%)
BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

VANCOUVER, BC and , /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)"BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, and...

PG : 123.16 (-0.60%)
BIOV.CN : 0.500 (-3.85%)
LMNGF : 0.3951 (-2.49%)

Key Turning Points

3rd Resistance Point 0.623
2nd Resistance Point 0.567
1st Resistance Point 0.533
Last Price 0.500
1st Support Level 0.443
2nd Support Level 0.387
3rd Support Level 0.353

See More

52-Week High 0.780
Fibonacci 61.8% 0.536
Last Price 0.500
Fibonacci 50% 0.460
Fibonacci 38.2% 0.384
52-Week Low 0.140

See More

Business Summary

BioVaxys Technology Corp is a clinical-stage immunotherapeutics company developing vaccine platforms for SARS-CoV-2 and various cancers.

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar